NCT01980628 - Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

July 31, 2016

Study Completion Date

October 2, 2017

Conditions

Marginal Zone LymphomaB-cell Lymphoma

Interventions

DRUG

ibrutinib

Trial Locations (25)

10065

Site Reference ID/Investigator # 200, New York

Site Reference ID/Investigator # 407, New York

11042

Site Reference ID/Investigator# 350, New Hyde Park

17033

Site Reference ID/Investigator# 220, Hershey

30322

Site Reference ID/Investigator# 033, Atlanta

33401

Site Reference ID/Investigator# 763, West Palm Beach

48202

Site Reference ID/Investigator# 195, Detroit

60611

Site Reference ID/Investigator# 370, Chicago

85719

Site Reference ID/Investigator# 837, Tucson

90095

Site Reference ID/Investigator# 377, Santa Monica

91010

Site Reference ID/Investigator# 047, Duarte

98109

Site Reference ID/Investigator# 348, Seattle

08724

Site Reference ID/Investigator# 745, New York

Unknown

Site Reference ID/Investigator# 560, Ghent

Site Reference ID/Investigator# 142, Pierre-Bénite

Site Reference ID/Investigator# 737, Rouen

Site Reference ID/Investigator# 750, Lille

Site Reference ID/Investigator# 749, La Roche-sur-Yon

Site Reference ID/Investigator# 736, Nantes

Site Reference ID/Investigator# 742, Rennes

Site Reference ID/Investigator# 735, Paris

Site Reference ID/Investigator# 669, Mainz

Site Reference ID/Investigator# 030, Manchester

Site Reference ID/Investigator# 814, Oxford

Site Reference ID/Investigator# 368, Plymouth